Hangzhou HealZen Therapeutics Co., Ltd. announced that its self‑developed Category 1 innovative drug, HZ‑A‑018 capsules, has received clinical approval from China’s National Medical Products Administration (NMPA) to conduct a Phase II trial for the monotherapy of chronic spontaneous urticaria (CSU). The highly selective BTK inhibitor adds a dermatologic autoimmune indication to its expanding pipeline spanning oncology and multiple immunology targets.
CSU Market Opportunity: Chronic spontaneous urticaria affects millions globally with limited effective options beyond antihistamines and omalizumab; BTK inhibition offers a novel mechanism targeting mast cell and B‑cell activation pathways.
Autoimmune Differentiation: Unlike first‑generation BTK inhibitors (ibrutinib) with cardiovascular and bleeding risks, HZ‑A‑018’s selectivity profile may enable safer chronic administration in autoimmune populations.
China‑First Development:NMPA approvals across five indications position HealZen for domestic leadership with potential global out‑licensing opportunities as clinical data matures.
Market Context
Factor
Impact
CSU Market Size
~ $2‑3 billion globally; high unmet need for refractory patients failing H1 antihistamines
BTK Inhibitor Evolution
Shift from oncology (B‑cell lymphoma) to autoimmune (RA, MS, ITP, urticaria); selective inhibitors preferred for chronic use
Competitive Landscape
Evobrutinib (Merck), fenebrutinib (Roche) in Phase III for MS; remibrutinib (Novartis) in CSU Phase III—HZ‑A‑018’s selectivity profile may differentiate
HealZen Positioning
Multi‑indication BTK platform rare among Chinese biotechs; supports Series B/C financing and M&A interest
Forward‑Looking Statements This brief contains forward‑looking statements regarding Phase II enrollment, efficacy outcomes across indications, and partnership potential for HZ‑A‑018. Actual results may differ due to risks including competitive BTK inhibitor development, autoimmune safety signals, and manufacturing scale‑up challenges.-Fineline Info & Tech
By Fineline Cube